The market for aesthetic injectables in the United States has historically been dominated by a select group of established pharmaceutical manufacturers. For over a decade, the market was structured as a tight oligopoly, with Allergan Aesthetics (Juvéderm), Galderma (Restylane), and Merz Aesthetics (Belotero, Radiesse) holding the vast majority of market share. However, the regulatory landscape has shifted significantly. Driven by advancements in polymer chemistry and new manufacturing technologies, a new generation of dermal fillers has secured U.S. Food and Drug Administration (FDA) Premarket Approval (PMA). These new approvals are diversifying the options available to clinical providers, allowing for highly customized treatments based on specific tissue depth, rheology, and facial dynamics.
The latest dermal fillers approved by the FDA include Evolysse Smooth and Evolysse Form (Symatese, approved February 13, 2025 under PMA P240022), saypha MagIQ (Croma-Pharma, approved September 8, 2025 under PMA P240008), and Belotero Volume (+) Lidocaine (Merz North America, approved May 19, 2026 under PMA P250020). Evolysse fillers are developed using advanced cross-linking technology to match natural tissue elasticity. Saypha MagIQ is a highly purified hyaluronic acid gel designed for broad facial rejuvenation. Belotero Volume (+) Lidocaine is a cohesive polydensified matrix (CPM) filler formulated with lidocaine for comfortable midface volume correction.
Evolysse (Symatese, approved Feb 13, 2025), saypha MagIQ (Croma-Pharma, approved Sept 8, 2025), and Belotero Volume (+) Lidocaine (Merz, approved May 19, 2026) are the latest FDA-approved dermal fillers.
For clinicians evaluating these new options, this guide provides a detailed analysis of their regulatory pathways, chemical cross-linking technologies, clinical trial data, and safety profiles.
What are the FDA PMA numbers and approval dates for the newest dermal fillers?
Unlike medical devices cleared through the 510(k) pathway by demonstrating "substantial equivalence" to a predicate device, dermal fillers are classified as Class III medical devices. Under FDA regulations, they must undergo the rigorous Premarket Approval (PMA) pathway. This requires prospective, multi-center clinical trials to demonstrate safety and effectiveness.
All dermal fillers intended for sub-epidermal injection are tracked under product code LMH (defined as "polysaccharide dermal filler"). The FDA's PMA database shows continuous activity under this code — a long tail of supplements to existing products plus a small number of brand-new base approvals. The 2025–2026 wave is defined by three new base HA filler approvals: Evolysse, saypha MagIQ, and Belotero Volume (+) Lidocaine. The specific approval details are as follows:
1. Evolysse Smooth and Evolysse Form (Symatese / Evolus)
Manufactured by French regenerative medicine specialist Symatese and commercialized in the U.S. by Evolus, the Evolysse line represents a significant entry. The system received its initial FDA PMA approval under number P240022 on February 13, 2025.
Subsequent supplements, including S001 (approved September 3, 2025) and S005 (approved February 27, 2026), expanded the labeling and manufacturing specifications. The initial approvals cover both Evolysse Smooth and Evolysse Form for the correction of moderate-to-severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 22.
2. saypha MagIQ (Croma-Pharma GmbH / Obagi)
Developed by Austrian HA manufacturer Croma-Pharma and brought to the U.S. market under the Obagi Medical brand (Waldencast), saypha MagIQ received FDA approval under P240008 on September 8, 2025. This approval brings Croma's long-established European formulation technology to the U.S. market.
The device is indicated for injection into the mid-to-deep dermis for the correction of moderate-to-severe facial wrinkles and folds (such as nasolabial folds) in adults. In a related development, Obagi Medical announced FDA approval of a second product in the line, saypha ChIQ, on June 15, 2026, indicated for cheek augmentation and correction of midface contour deficiencies, which expands their U.S. portfolio.
3. Belotero Volume (+) Lidocaine (Merz North America, Inc.)
Merz Aesthetics expanded its established Belotero line with the approval of Belotero Volume (+) Lidocaine under P250020 on May 19, 2026. While the original Belotero Balance is a cohesive polydensified matrix (CPM) filler optimized for superficial fine lines, the new Volume formulation is designed for deep tissue placement.
The (+) Lidocaine designation reflects the integration of 0.3% lidocaine hydrochloride to reduce injection discomfort. It is cleared for deep (subcutaneous and/or supraperiosteal) injection to correct mid-face volume deficits and contour deficiencies in adults over 22.
| Regulatory Parameter | Evolysse Smooth / Form | saypha MagIQ | Belotero Volume (+) Lidocaine |
|---|---|---|---|
| Manufacturer | Symatese (France) | Croma-Pharma GmbH (Austria) | Merz North America, Inc. (USA) |
| U.S. Distributor | Evolus, Inc. | Obagi Cosmeceuticals LLC | Merz Aesthetics |
| PMA Number | P240022 | P240008 | P250020 |
| Approval Date | February 13, 2025 | September 8, 2025 | May 19, 2026 |
| Product Code | LMH | LMH | LMH |
| Injection Depth | Mid-to-deep dermis | Mid-to-deep dermis | Subcutaneous / Supraperiosteal |
| Indication | Moderate-to-severe nasolabial folds | Moderate-to-severe wrinkles & folds | Midface volume deficit correction |
How do the chemical properties and cross-linking technologies compare?
The clinical performance of a dermal filler — including its lift capacity, tissue integration, longevity, and swelling behavior — is determined by its physical chemistry. Hyaluronic acid in its natural state is a linear polysaccharide that is rapidly degraded by the body's endogenous hyaluronidase enzymes within 24 to 48 hours. To make it stable enough for clinical use, manufacturers cross-link the HA chains using chemical agents, most commonly butanediol diglycidyl ether (BDDE). The differences in how these chains are cross-linked define the unique properties of each filler line.
Evolysse's Advanced Cross-Linking Technology
Symatese developed the Evolysse range using a patented, low-energy cross-linking process designed to protect the natural long-chain structure of high-molecular-weight HA. This approach minimises the amount of BDDE required to achieve stability.
- Dynamic Matching: The technology focuses on matching the natural elasticity of facial tissue. By keeping the polymer structure flexible, the gel integrates smoothly into the extracellular matrix of the dermis. This allows the filler to deform and recover naturally during facial expressions, reducing the risk of a stiff or artificial appearance.
- Formulation Options: The line includes Evolysse Smooth (for finer, superficial folds) and Evolysse Form (for deeper dermal placement), which differ in their HA concentration and cross-linking density.
saypha MagIQ's MACRO Double Cross-Linking
Croma-Pharma utilizes its proprietary MACRO (Minimal Cross-linking & Optimized Rheology) technology to formulate saypha MagIQ.
- Purification and Homogenization: The process begins with ultra-high-molecular-weight HA chains that undergo a double-cross-linking step using BDDE. This is followed by an extraction phase that removes unreacted cross-linker and free HA fragments.
- Physical Properties: The resulting gel is highly purified and monophasic, featuring a high elastic modulus ($G'$) and cohesive properties. This structure gives the filler strong resistance to enzymatic degradation while ensuring smooth, predictable extrusion through fine-gauge needles.
Belotero Volume's Cohesive Polydensified Matrix (CPM)
Merz Aesthetics uses a multi-step manufacturing process to create its Cohesive Polydensified Matrix (CPM) technology. Unlike traditional monophasic or biphasic fillers, CPM gels contain zones of varying density.
- The CPM Process: The manufacturing process involves cross-linking HA with BDDE, adding more purified HA, and cross-linking the mixture again. This creates a gel with both highly cross-linked, dense zones and less cross-linked, lighter zones.
- Clinical Benefits: When injected, the lower-density zones allow the filler to integrate smoothly into the surrounding tissue, filling micro-depressions. Meanwhile, the higher-density zones provide the structural support and lift required for deep volume correction. Belotero Volume (+) Lidocaine combines this dual-density structure with a high G' to deliver support in the cheek and midface, while the integrated lidocaine ensures patient comfort.
| Rheological Property | Evolysse Form | saypha MagIQ | Belotero Volume (+) Lidocaine |
|---|---|---|---|
| HA Concentration | Per labeling (Cold-X™ process) | 23 mg/mL (Croma standard) | 25.5 mg/mL |
| Cross-linking Agent | BDDE | BDDE | BDDE |
| Technology | Low-energy flexible HA | MACRO Double Cross-linking | Cohesive Polydensified Matrix (CPM) |
| Gel Characteristics | Monophasic, high elasticity | Monophasic, highly cohesive | Monophasic, polydensified matrix |
| Elastic Modulus ($G'$) | Moderate | High | Very High |
| Lidocaine Content | None (in initial Form/Smooth) | None (in MagIQ; ChIQ has lidocaine) | 0.3% Lidocaine Hydrochloride |
Exact HA concentration follows each product's FDA-approved labeling; all three sit in a similar ~20–25.5 mg/mL range, so cross-linking technology — not concentration — is the real differentiator.
What clinical trial data supports the efficacy and safety of these new fillers?
To secure U.S. market access, these formulations had to demonstrate non-inferiority to existing gold-standard fillers in prospective trials. The data submitted to the FDA provides a clear picture of their performance and safety profiles.
Clinical Trials for Evolysse (Symatese / Evolus)
Evolysse's FDA approval (P240022) rested on a pivotal randomized, evaluator-blinded study of 140 patients that demonstrated non-inferiority to an active comparator (Restylane-L) for the correction of moderate-to-severe facial wrinkles and folds. A separate post-market "real-life" evaluation is registered under NCT07385053 ("Real-Life Evaluation of the HA Dermal Filler") to confirm performance under everyday clinical conditions.
- Safety Outcomes: Adverse events were dominated by transient, localized injection-site reactions (bruising, swelling, pain, and redness) that resolved within several days. No signal for delayed-onset nodules or hypersensitivity was reported in the submitted data.
Clinical Trials for saypha MagIQ (Croma-Pharma)
Croma-Pharma's U.S. clearance was supported by a pivotal nasolabial-fold study (the FDA's PMA record for P240008 lists study NCT03990883), demonstrating effectiveness maintained out to 24 weeks on standard wrinkle-severity grading.
- Related European Evidence: An earlier Croma randomized, evaluator-blinded study (NCT05386030) established non-inferiority of saypha VOLUME Lidocaine against Juvéderm Voluma XC for midface volume deficiency — evidence that underpins the saypha line's cross-linking platform.
- Post-Market Study: A real-world effectiveness study of Obagi saypha MagIQ for volume loss and fine lines is registered under NCT07421544. The safety analysis showed a low overall rate of complications, and the double-cross-linked structure did not produce an increase in foreign-body reactions or granulomas.
Clinical Trials for Belotero Volume (+) Lidocaine (Merz)
Merz submitted data demonstrating the safety and effectiveness of deep facial injections:
- Trial Protocol: A prospective, multi-center study evaluating mid-face volume correction, consistent with the established Belotero Volume clinical program.
- Efficacy Results: Belotero Volume demonstrated effective correction of mid-face volume deficits. As a high-G' volumizer, its deep, cohesive structure is designed for durable structural support rather than superficial smoothing.
- Safety Profile: The addition of 0.3% lidocaine reduced injection discomfort relative to non-lidocaine formulations. The safety profile was favorable, with a low incidence of persistent swelling of the kind that can occasionally affect high-volume cheek injections.
How the new fillers compare to the established incumbents
The three new approvals are not entering an empty market. Each is positioned against an entrenched incumbent, and the differentiator is chemistry and rheology rather than a brand-new indication:
- Evolysse (Symatese / Evolus) vs. Juvéderm Ultra XC / Restylane-L: Evolysse's Cold-X™ low-energy cross-linking is marketed as preserving long-chain HA for a softer, more elastic feel. It is approved for moderate-to-severe facial wrinkles and folds (nasolabial folds) — the same indication Juvéderm Ultra XC and Restylane-L have held for over a decade. The pitch is natural tissue integration and dynamic movement, not a new anatomical zone.
- saypha MagIQ (Croma-Pharma / Obagi) vs. Juvéderm Ultra XC / Restylane-L: MagIQ is a mid-to-deep dermal nasolabial-fold filler built on Croma's MACRO double cross-linking platform — the same technology behind the long-running European saypha (formerly Princess) line. For U.S. providers, it adds a third HA chemistry to a crowded nasolabial-fold field.
- Belotero Volume (+) Lidocaine (Merz) vs. Juvéderm Voluma XC / Restylane Lyft: This is the most directly competitive entrant. Belotero Volume is a deep, high-G' volumizer for midface volume deficit — squarely against Voluma and Restylane Lyft. Merz already owns Belotero Balance (superficial) and Radiesse (CaHA); Volume (+) Lidocaine fills the deep-volumizer gap in its own portfolio.
The practical read: all three treat indications the incumbents already cover. The clinical question is whether a specific rheology — softer integration, higher lift, or integrated lidocaine — fits a specific patient better, not whether any of these opens a new treatment zone. New does not automatically mean better.
Safety: vascular risk, delayed nodules, and reversibility
Because all three are hyaluronic-acid fillers, they share a common — and clinically important — safety profile:
- Vascular occlusion is the most serious acute risk. Any HA filler injected into or near a vessel can occlude it; the midface, periorbital, glabellar, and nasal regions carry the highest danger. Symptoms include blanching, pain, duskiness, and (in the periorbital region) vision changes. Every HA filler appointment should have hyaluronidase immediately available, and injectors should use appropriate technique (low injection pressure, aspiration where relevant, cannulas in high-risk planes). Our dedicated guides cover filler vascular occlusion and the hyaluronidase emergency kit.
- Delayed-onset nodules can appear weeks to months after injection. These are usually inflammatory rather than infectious and are typically managed with hyaluronidase, intralesional corticosteroid, or both. The FDA convened a General Issues Panel on dermal fillers in August 2025 specifically to discuss nodule and safety signals as fillers move into new facial zones.
- Reversibility is the key advantage over biostimulators. Unlike Sculptra (PLLA), Radiesse (CaHA), or Bellafill (PMMA), HA fillers can be dissolved with hyaluronidase if there is occlusion, misplacement, overcorrection, or dissatisfaction. The newer HA entrants inherit this safety margin.
- Lidocaine content affects comfort, not vascular risk. Belotero Volume (+) and (separately) saypha ChIQ include 0.3% lidocaine; the initial Evolysse Form/Smooth and MagIQ presentations do not. Lidocaine reduces injection discomfort but does not change the vascular-risk calculus.
Market Dynamics: Shifting the Clinical Oligopoly
The introduction of these new fillers provides clinical practices with several strategic advantages:
- Chemical Diversity: Providers are no longer limited to a few standard HA technologies. They can select Evolysse's flexible matrix for highly expressive areas (like the perioral zone) to maintain natural motion, saypha MagIQ for precise dermal smoothing, or Belotero Volume's CPM structure for deep, integrated structural support.
- Portfolio Competition: The entry of Evolus (commercializing Evolysse) and Obagi (distributing saypha) introduces new commercial competition. This pressure is expected to lower per-syringe acquisition costs for clinics, allowing for more flexible patient pricing.
- Customization: The ability to mix and match fillers with different rheological profiles allows injectors to perform multi-layered rejuvenation, placing structural fillers supraperiosteally and highly integrated, flexible fillers in the superficial dermis.
Choosing among Evolysse, saypha MagIQ, and Belotero Volume
For a provider, product selection is driven by depth, lift, and tissue dynamics rather than launch date:
- Choose Evolysse (Form or Smooth) for areas that move — perioral lines and dynamic nasolabial folds — where a softer, elastic gel that integrates with the tissue is valued over rigid lift.
- Choose saypha MagIQ for mid-to-deep dermal smoothing of moderate nasolabial folds, particularly for practices wanting a third HA chemistry alongside the Allergan and Galderma defaults.
- Choose Belotero Volume (+) Lidocaine for midface volume loss and contour deficiency requiring deep, structural support and lift, with integrated lidocaine for injection comfort.
None of these is a "better" filler in the abstract. Selection should follow the patient's anatomy, the intended injection plane, and the injector's experience with that specific rheology. A provider who has not been trained on a new product should not assume it handles like the incumbent it superficially resembles — extrusion force, lift capacity, and swelling behavior all differ.
Frequently Asked Questions
What is the difference between Evolysse Form and Evolysse Smooth?
While both fillers belong to the same product family and are approved under the same PMA (P240022), they are engineered for different tissue depths and indications:
- Evolysse Smooth: Formulated with a lower concentration of hyaluronic acid and a lower cross-linking density. It has a lower viscosity and elastic modulus ($G'$), allowing it to flow easily into superficial dermal layers. It is indicated for correcting fine-to-moderate wrinkles and lines, such as superficial nasolabial folds and perioral lines.
- Evolysse Form: Formulated with a higher concentration of HA and a denser cross-linking structure. This gives it a higher elastic modulus and greater lift capacity. It is designed for injection into the mid-to-deep dermis, targeting moderate-to-severe folds and volume deficits that require more structural support.
What is the FDA-approved indication for saypha MagIQ?
The FDA has approved saypha MagIQ for injection into the mid-to-deep dermis for the correction of moderate-to-severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.
While clinicians may use it off-label for other areas (such as lip augmentation or tear trough correction) based on clinical judgment, the clinical safety and efficacy data submitted to the FDA for PMA approval focused on the correction of nasolabial folds.
Are these new hyaluronic acid fillers reversible?
Yes. Because Evolysse, saypha MagIQ, and Belotero Volume are formulated from hyaluronic acid, they are fully reversible.
If a patient experiences an adverse event (such as vascular occlusion from an accidental intravascular injection) or is dissatisfied with the cosmetic result, the filler can be dissolved. This is achieved by injecting hyaluronidase, an enzyme that breaks down the cross-linked HA polymer into soluble fragments that the body's lymphatic system can rapidly clear.
For safety, clinics should always have a dedicated hyaluronidase emergency kit on hand before performing any HA filler treatment.
How long do Evolysse, saypha MagIQ, and Belotero Volume last?
All three are HA fillers, and longevity depends more on placement depth, injection volume, and the patient's metabolism than on the brand name. As a general frame:
- Superficial/deep dermal nasolabial-fold fillers (Evolysse, saypha MagIQ): effectiveness is typically maintained out to roughly 6 months (24 weeks), which is the primary endpoint used in the pivotal trials; many patients return for repeat treatment in the 6–12 month window.
- Deep volumizers (Belotero Volume): high-G' products placed supraperiosteally in the midface tend to last longer than superficial dermal fillers, often toward the upper end of the 9–18 month range, because there is less muscular movement at that depth.
These are general patterns, not guarantees. Individual results vary, and each product's FDA-approved labeling is the authoritative source on durability.
Sources
- FDA PMA Database: EVOLYSSE SMOOTH and EVOLYSSE FORM (P240022). February 13, 2025. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240022
- FDA PMA Database: saypha MagIQ (P240008). September 8, 2025. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240008
- FDA PMA Database: Belotero Volume (+) Lidocaine (P250020). May 19, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250020
- Waldencast / Obagi Medical. FDA Approval of Obagi saypha ChIQ Injectable HA Gel. June 15, 2026. https://ir.waldencast.com/news-releases/news-release-details/obagi-medical-announces-fda-approval-obagir-sayphar-chiqtm
- ClinicalTrials.gov. Study NCT07385053: Real-Life Evaluation of the HA Dermal Filler. https://clinicaltrials.gov/study/NCT07385053
- ClinicalTrials.gov. Study NCT03990883: saypha MagIQ Pivotal Study (per FDA PMA P240008 record). https://clinicaltrials.gov/study/NCT03990883
- ClinicalTrials.gov. Study NCT05386030: saypha VOLUME Lidocaine vs Juvéderm Voluma XC (Midface). https://clinicaltrials.gov/study/NCT05386030
- ClinicalTrials.gov. Study NCT07421544: Real-World Effectiveness of Obagi saypha MagIQ. https://clinicaltrials.gov/study/NCT07421544
- Hyaluronic Acid Dermal Fillers and PMA Approvals: Market Overview. PMA approvals
- Merz Aesthetics Injectable Portfolio: Xeomin, Radiesse, and Belotero.
- American Society of Plastic Surgeons (ASPS): Dermal Fillers Guide. https://www.plasticsurgery.org/cosmetic-procedures/dermal-fillers
